Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation

Roberto Fogari; Amedeo Mugellini; Annalisa Zoppi; Paola Preti; Maurizio Destro; Pierangelo Lazzari; Giuseppe Derosa

doi:10.1177/1074248410395018

Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation

Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, Paola Preti, Maurizio Destro, Pierangelo Lazzari, Giuseppe Derosa

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

This study evaluated the effect of telmisartan, ramipril, and amlodipine on atrial fibrillation (AF) recurrence and severity in hypertensive patients with metabolic syndrome. A total of 391 hypertensive outpatients with metabolic syndrome, in sinus rhythm but with at least 2 episodes of AF in the previous 6 months were randomized to telmisartan, ramipril, or amlodipine for 1 year. At the first AF, ventricular rate (VR) and plasma cardiac troponin I (TnI) were evaluated. P-wave dispersion (PWD) and procollagen type I carboxy-terminal peptide (PIP) were evaluated before and after 12 months of treatment. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were similarly and significantly reduced by all treatments (P

Original language	English
Pages (from-to)	34-43
Number of pages	10
Journal	Journal of Cardiovascular Pharmacology and Therapeutics
Volume	17
Issue number	1
DOIs	https://doi.org/10.1177/1074248410395018
Publication status	Published - Mar 2012

Keywords

amlodipine
atrial fibrillation
hypertension
ramipril
telmisartan

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Cardiology and Cardiovascular Medicine

Access to Document

10.1177/1074248410395018

Fingerprint Dive into the research topics of 'Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation'. Together they form a unique fingerprint.

Cite this

Fogari, R., Mugellini, A., Zoppi, A., Preti, P., Destro, M., Lazzari, P., & Derosa, G. (2012). Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 17(1), 34-43. https://doi.org/10.1177/1074248410395018

Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. / Fogari, Roberto; Mugellini, Amedeo; Zoppi, Annalisa; Preti, Paola; Destro, Maurizio; Lazzari, Pierangelo; Derosa, Giuseppe.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 17, No. 1, 03.2012, p. 34-43.

Research output: Contribution to journal › Article › peer-review

Fogari, R, Mugellini, A, Zoppi, A, Preti, P, Destro, M, Lazzari, P & Derosa, G 2012, 'Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation', Journal of Cardiovascular Pharmacology and Therapeutics, vol. 17, no. 1, pp. 34-43. https://doi.org/10.1177/1074248410395018

Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics. 2012 Mar;17(1):34-43. https://doi.org/10.1177/1074248410395018

Fogari, Roberto ; Mugellini, Amedeo ; Zoppi, Annalisa ; Preti, Paola ; Destro, Maurizio ; Lazzari, Pierangelo ; Derosa, Giuseppe. / Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2012 ; Vol. 17, No. 1. pp. 34-43.

@article{eac4cec060cd41cb9ecb8fb520e2d8c1,

title = "Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation",

abstract = "This study evaluated the effect of telmisartan, ramipril, and amlodipine on atrial fibrillation (AF) recurrence and severity in hypertensive patients with metabolic syndrome. A total of 391 hypertensive outpatients with metabolic syndrome, in sinus rhythm but with at least 2 episodes of AF in the previous 6 months were randomized to telmisartan, ramipril, or amlodipine for 1 year. At the first AF, ventricular rate (VR) and plasma cardiac troponin I (TnI) were evaluated. P-wave dispersion (PWD) and procollagen type I carboxy-terminal peptide (PIP) were evaluated before and after 12 months of treatment. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were similarly and significantly reduced by all treatments (P ",

keywords = "amlodipine, atrial fibrillation, hypertension, ramipril, telmisartan",

author = "Roberto Fogari and Amedeo Mugellini and Annalisa Zoppi and Paola Preti and Maurizio Destro and Pierangelo Lazzari and Giuseppe Derosa",

year = "2012",

month = mar,

doi = "10.1177/1074248410395018",

language = "English",

volume = "17",

pages = "34--43",

journal = "Journal of Cardiovascular Pharmacology and Therapeutics",

issn = "1074-2484",

publisher = "SAGE Publications Ltd",

number = "1",

}

TY - JOUR

T1 - Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation

AU - Fogari, Roberto

AU - Mugellini, Amedeo

AU - Zoppi, Annalisa

AU - Preti, Paola

AU - Destro, Maurizio

AU - Lazzari, Pierangelo

AU - Derosa, Giuseppe

PY - 2012/3

Y1 - 2012/3

N2 - This study evaluated the effect of telmisartan, ramipril, and amlodipine on atrial fibrillation (AF) recurrence and severity in hypertensive patients with metabolic syndrome. A total of 391 hypertensive outpatients with metabolic syndrome, in sinus rhythm but with at least 2 episodes of AF in the previous 6 months were randomized to telmisartan, ramipril, or amlodipine for 1 year. At the first AF, ventricular rate (VR) and plasma cardiac troponin I (TnI) were evaluated. P-wave dispersion (PWD) and procollagen type I carboxy-terminal peptide (PIP) were evaluated before and after 12 months of treatment. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were similarly and significantly reduced by all treatments (P

AB - This study evaluated the effect of telmisartan, ramipril, and amlodipine on atrial fibrillation (AF) recurrence and severity in hypertensive patients with metabolic syndrome. A total of 391 hypertensive outpatients with metabolic syndrome, in sinus rhythm but with at least 2 episodes of AF in the previous 6 months were randomized to telmisartan, ramipril, or amlodipine for 1 year. At the first AF, ventricular rate (VR) and plasma cardiac troponin I (TnI) were evaluated. P-wave dispersion (PWD) and procollagen type I carboxy-terminal peptide (PIP) were evaluated before and after 12 months of treatment. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were similarly and significantly reduced by all treatments (P

KW - amlodipine

KW - atrial fibrillation

KW - hypertension

KW - ramipril

KW - telmisartan

UR - http://www.scopus.com/inward/record.url?scp=84856956291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856956291&partnerID=8YFLogxK

U2 - 10.1177/1074248410395018

DO - 10.1177/1074248410395018

M3 - Article

C2 - 21335482

AN - SCOPUS:84856956291

VL - 17

SP - 34

EP - 43

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 1

ER -